Chitosan hydrogel as sirna vector for prolonged gene silencing

Journal of Nanobiotechnology

Volumn 12, Issue 1, 2014, Pages

  Ma, Zhiwei ^a   Yang, Chuanxu ^b   Song, Wen ^a   Wang, Qintao ^a   Kjems, Jørgen ^b   Gao, Shan ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; DEGRADATION; ENZYMES; HYDROGELS; CHITIN;

CHITOSAN HYDROGEL; DEGRADATION RATE; FLUORESCENT SIGNALS; GENE SILENCING; PERIODONTAL DISEASE; POTENTIAL THERAPIES; THERAPEUTIC STRATEGY; THERMO SENSITIVE;

GENE THERAPY;

CHITOSAN; LYSOZYME; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SMALL INTERFERING RNA; CARBOCYANINE; CYANINE DYE 5; DRUG CARRIER; HYDROGEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; CELL VIABILITY; COMPARATIVE STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENZYME DEGRADATION; GENE SILENCING; GENETIC TRANSFECTION; HEAT SENSITIVITY; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; RNA VECTOR; SUSTAINED DRUG RELEASE; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG STABILITY; FEMALE; GENETICS; CONTROLLED STUDY; DRUG RELEASE; MACROPHAGE; RNA INTERFERENCE;

MUS;

ANIMALS; CARBOCYANINES; CELL LINE; CELL SURVIVAL; CHITOSAN; DRUG CARRIERS; DRUG STABILITY; FEMALE; GENE SILENCING; HYDROGEL; MICE; MICE, INBRED BALB C; MURAMIDASE; RNA, SMALL INTERFERING;

EID: 84902693932     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-12-23     Document Type: Article

References (34)

1. Koide M, Kinugawa S, Takahashi N, Udagawa N. Osteoclastic bone resorption induced by innate immune responses. Periodontol 2000 2010, 54:235-246.
2. Lopez-Fraga M, Martinez T, Jimenez A. RNA interference technologies and therapeutics: from basic research to products. BioDrugs 2009, 23:305-332.
3. Sotillo E, Thomas-Tikhonenko A. Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther 2011, 131:18-32.
4. Gonzalez-Alegre P. Therapeutic RNA interference for neurodegenerative diseases: from promise to progress. Pharmacol Ther 2007, 114:34-55.
5. Lupberger J, Brino L, Baumert TF. RNAi: a powerful tool to unravel hepatitis C virus-host interactions within the infectious life cycle. J Hepatol 2008, 48:523-525.
6. Laroui H, Theiss AL, Yan Y, Dalmasso G, Nguyen HT, Sitaraman SV, Merlin D. Functional TNFalpha gene silencing mediated by polyethyleneimine/TNFalpha siRNA nanocomplexes in inflamed colon. Biomaterials 2011, 32:1218-1228.
7. Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, Kjems J. Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 2009, 17:162-168.
8. Nawroth I, Alsner J, Behlke MA, Besenbacher F, Overgaard J, Howard KA, Kjems J. Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFalpha prevents radiation-induced fibrosis. Radiother Oncol 2010, 97:143-148.
9. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG. Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 2010, 267:9-21.
10. Duceppe N, Tabrizian M. Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery. Expert Opin Drug Deliv 2010, 7:1191-1207.
11. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MO, Hovgaard MB, Schmitz A, Nyengaard JR, Besenbacher F, Kjems J. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 2006, 14:476-484.
12. Holzerny P, Ajdini B, Heusermann W, Bruno K, Schuleit M, Meinel L, Keller M. Biophysical properties of chitosan/siRNA polyplexes: profiling the polymer/siRNA interactions and bioactivity. J Control Release 2012, 157:297-304.
13. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol 2010, 56:290-299.
14. Ramakrishnan S. Hydrogel-siRNA for cancer therapy. Cancer Biol Ther 2011, 11:849-851.
15. Jo S, Kim S, Cho TH, Shin E, Hwang SJ, Noh I. Effects of recombinant human bone morphogenic protein-2 and human bone marrow-derived stromal cells on in vivo bone regeneration of chitosan-poly(ethylene oxide) hydrogel. J Biomed Mater Res A 2013, 101:892-901.
16. Chakavala SR, Patel NG, Pate NV, Thakkar VT, Patel KV, Gandhi TR. Development and in vivo evaluation of silver sulfadiazine loaded hydrogel consisting polyvinyl alcohol and chitosan for severe burns. J Pharm Bioallied Sci 2012, 4:S54-S56.
17. Ahmadi R, de Bruijn JD. Biocompatibility and gelation of chitosan-glycerol phosphate hydrogels. J Biomed Mater Res A 2008, 86:824-832.
18. Hoemann CD, Chenite A, Sun J, Hurtig M, Serreqi A, Lu Z, Rossomacha E, Buschmann MD. Cytocompatible gel formation of chitosan-glycerol phosphate solutions supplemented with hydroxyl ethyl cellulose is due to the presence of glyoxal. J Biomed Mater Res A 2007, 83:521-529.
19. Ruel-Gariepy E, Chenite A, Chaput C, Guirguis S, Leroux J. Characterization of thermosensitive chitosan gels for the sustained delivery of drugs. Int J Pharm 2000, 203:89-98.
20. Kim S, Nishimoto SK, Bumgardner JD, Haggard WO, Gaber MW, Yang Y. A chitosan/beta-glycerophosphate thermo-sensitive gel for the delivery of ellagic acid for the treatment of brain cancer. Biomaterials 2010, 31:4157-4166.
21. Wang L, Stegemann JP. Thermogelling chitosan and collagen composite hydrogels initiated with beta-glycerophosphate for bone tissue engineering. Biomaterials 2010, 31:3976-3985.
22. Cheng YH, Yang SH, Lin FH. Thermosensitive chitosan-gelatin-glycerol phosphate hydrogel as a controlled release system of ferulic acid for nucleus pulposus regeneration. Biomaterials 2011, 32:6953-6961.
23. Seth S, Johns R, Templin MV. Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects. Ther Deliv 2012, 3:245-261.
24. Manaka T, Suzuki A, Takayama K, Imai Y, Nakamura H, Takaoka K. Local delivery of siRNA using a biodegradable polymer application to enhance BMP-induced bone formation. Biomaterials 2011, 32:9642-9648.
25. Saito T, Tabata Y. Preparation of gelatin hydrogels incorporating small interfering RNA for the controlled release. J Drug Target 2012, 20:864-872.
26. Krebs MD, Jeon O, Alsberg E. Localized and sustained delivery of silencing RNA from macroscopic biopolymer hydrogels. J Am Chem Soc 2009, 131:9204-9206.
27. Han HD, Mora EM, Roh JW, Nishimura M, Lee SJ, Stone RL, Bar-Eli M, Lopez-Berestein G, Sood AK. Chitosan hydrogel for localized gene silencing. Cancer Biol Ther 2011, 11:839-845.
28. Akncbay H, Senel S, Ay ZY. Application of chitosan gel in the treatment of chronic periodontitis. J Biomed Mater Res B Appl Biomater 2007, 80:290-296.
29. Lee KY, Ha WS, Park WH. Blood compatibility and biodegradability of partially N-acylated chitosan derivatives. Biomaterials 1995, 16:1211-1216.
30. Onishi H, Machida Y. Biodegradation and distribution of water-soluble chitosan in mice. Biomaterials 1999, 20:175-182.
31. Tomihata K, Ikada Y. In vitro and in vivo degradation of films of chitin and its deacetylated derivatives. Biomaterials 1997, 18:567-575.
32. Lim SM, Song DK, Oh SH, Lee-Yoon DS, Bae EH, Lee JH. In vitro and in vivo degradation behavior of acetylated chitosan porous beads. J Biomater Sci Polym Ed 2008, 19:453-466.
33. Iversen F, Yang C, Dagnaes-Hansen F, Schaffert DH, Kjems J, Gao S. Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice. Theranostics 2013, 3:201-209.
34. Nawroth I, Alsner J, Deleuran BW, Dagnaes-Hansen F, Yang C, Horsman MR, Overgaard J, Howard KA, Kjems J, Gao S. Peritoneal macrophages mediated delivery of chitosan/siRNA nanoparticle to the lesion site in a murine radiation-induced fibrosis model. Acta Oncol (Stockholm, Sweden) 2013, 52:1730-1738.